Pharmaceutical company Gilead Sciences announced Monday its intention to acquire Ouro Medicines, a privately-owned biotechnology company, in a transaction that could reach $2.18 billion in total value.
The acquisition represents a major investment by Gilead in expanding its biotechnology portfolio through the purchase of the private firm.
